Nitrates as adjunct hypertensive treatment

Current Hypertension Reports

Volumn 8, Issue 1, 2006, Pages 60-68

  Stokes, Gordon S ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIURETIC AGENT; EPROSARTAN; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTERY DISEASE; ARTERY WALL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; GERIATRIC CARE; HEADACHE; HEART DISEASE; HEART FAILURE; HEREDITY; HUMAN; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PULSE PRESSURE; PULSE WAVE; REVIEW; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; NITRATES; TREATMENT OUTCOME;

EID: 33646026994     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0042-7     Document Type: Review

References (46)

1. Weber M: Introduction: hypertension in the elderly. Am J Geriatr Cardiol 2000, 9:11.
2. Franklin SS: Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist's point of view. Pathol Biol (Paris) 1999, 47:594-603.
3. Perry HM, Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465-471.
4. Stokes GS: Systolic hypertension of the elderly: pushing the frontiers of therapy - a suggested new approach. J Clin Hypertens 2004, 6:192-197.
5. Murrell W: Nitroglycerine as a remedy for angina pectoris. Lancet 1879, 80:80-227.
6. Duchier J, Iannascoli F, Safar M: Antihypertensive effect of sustained-release isosorbide dlnltrate for isolated systolic systemic hypertension in the elderly. Am J Cardiol 1987, 60:99-102.
7. Stokes GS, Ryan M: Can extended-release isosorbide mononitrate be used as adjunctive therapy for systolic hypertension? An open study employing pulse-wave analysis to determine effects of antihypertensive therapy. Am J Geriat Cardiol 1997, 6:11-19.
8. Stokes GS, Ryan M, Brnabic A, Nyberg G: A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension. J Hypertens 1999, 17:1767-1773.
9. Przewlocka-Kosmala M: [Effect of isosorbide mononitrate on hypotensive action of enalapril in patients with mild and moderate hypertension.]. Pol Merkuriusz Lek 2002, 13:40-42.
10. Stokes GS, Bune AJ, Huon N, Barin ES: Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension. Hypertension 2005, 45:380-384.
11. Nesbitt SD: Nitrates as adjunct hypertensive treatment: a possible answer to resistant systolic hypertension. Hypertension 2005, 45:352-353.
12. Stokes, Barin ES, Gilfillan KL: Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003, 41:297-301.
13. Lauer T, Heib C, Preik M, et al.: Reduction in peripheral flow reserve impairs endothelial function in conduit arteries of patients with essential hypertension. J Hypertens 2005, 23:563-569.
14. Mitchell GF, Parise H, Vita JA, et al.: Local shear stress and brachial artery flow-mediated dilation. The Framingham Heart Study. Hypertension 2004, 44:134-139.
15. Doughty JM, Langton PD: A transient dilatation of pressurized rat cerebral arteries during rapid pressure increases is mediated by nitric oxide. Pflugers Arch Eur J Physiol 1998, 436:220-226.
16. Macha M, Yamazaki K, Gordon LM, et al.: The vasoregulatory role of endothelium derived nitric oxide during pulsatile cardiopulmonary bypass. ASAIO J 1996, 42:M800-M804.
17. Stokes GS: A dynamic role of NO in the small artery conduits of the systemic circulation. Physiol Res 2002, 51:57P.
18. Bellien J, Joannides R, Iacob M, et al.: Calcium-activated potassium channels and NO regulate human peripheral conduit artery mechanics. Hypertension 2005, 46:210-216.
19. Kojda G, Harrison DG: Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999, 43:562-571.
20. Pauca AL, Kon ND, O'Rourke MF: Benefit of nitroglycerin on arterial stiffness is directly due to effects on peripheral arteries. Heart 2005, 91:1428-1432.
21. Safar ME, O'Rourke MF: Pulse pressure and antihypertensive agents. Hypertension 2005, 46:e6.
22. Panza JA, Quyyumi AA, Brush JE, et al.: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22-27.
23. Brosnan MJ, Hamilton CA, Graham D, et al.: Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002, 20:281-286.
24. Schiffrin EL, Deng Li-Y: Comparison of effects of angiotensin I-converting enzyme inhibition and [beta]-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995, 25:699-703.
25. Ghiadoni L, Magagna A, Versari D, et al.: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003, 41:1281-1286.
26. Kiowski W, Linder L, Nuesch R, et al.: Effect of cilazopril on vascular structure and function in essential hypertension. Hypertension 1996, 27:371-376.
27. Rizzoni D, Muiesan ML, Porteri E, et al.: Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997, 15:197-204.
28. Van der Linde NAJ, Hoomsma F, van der Meiracker AH: Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. J Hypertens 2005, 23:1009-1015.
29. Taddei S, Grassi G: Angiotensin II as the link between nitric oxide and neurogenic function. J Hypertens 2005, 23:935-937.
30. Brunner H, Cockcroft JR, Deanfield J, et al.: Endothelial function and dysfunction. Part II; Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233-246.
31. Franklin SS, Gustin WIV, Wong ND, et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997, 96:308-315.
32. Duggirala MK, Cuddihy RM, Cuddihy M-T, et al.: Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005, 18:833-838.
33. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
34. Persu A, Vinck WJ, El Khattabi OE, et al.: Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study. J Hypertens 2005, 23:759-765.
35. Yamashita T, Kawashima S, Ohashi Y, et al.: Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice over-expressing endothelial nitric oxide synthase. Hypertension 2000, 36:97-102.
36. Li R, Lyn D, Lapu-Bula R, et al.: Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African-Americans. Am J Hypertens 2004, 17:560-567.
37. Starmans-Kool MJ, Kleinjans HA, Lustermans FA, et al.: Treatment of elderly patients with isolated systolic hypertension with isosorbide in an asymmetric dosing schedule. J Hum Hypertens 1998, 12:557-561.
38. Felizardo A, Maldonado J, Pego M, et al.: Role of nitrates in pharmacologic modulation of reflected waves and their significance in the treatment of arterial hypertension of the elderly. Rev Port Cardiol 1997, 16:607-611.
39. Stokes GS, Barin ES, Gilfillan KL, Kaesemeyer WH: Interactions of L-arginine, isosorbide mononitrate and angiotensin II inhibition on arterial pulse wave. Am J Hypertens 2003, 16:719-724.
40. Tingberg E, Roijer A, Thilen U, et al.: Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 2003, 145:E1.
41. Muller S, Konig I, Meyer W, Kojda G: Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol 2004, 44:624-631.
42. O'Rourke MF, Safar ME: Relationship between aortic stiffening and microvascular disease in brain and kidney. Cause and logic of therapy. Hypertension 2005, 46:200-204.
43. Allbutt C: Senile plethora or high arterial pressure in elderly persons. In Classic Papers in Hypertension, Blood Pressure and Renin. Edited by Swales JD. London: Science Press; 1987:104-123.
44. Bitar F, Akhter MW, Khan H, Elkayam U: Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. 2004, 94:1465-1468.
45. Nyberg G: Current status of isosorbide-5-mononitrate therapy in chronic stable angina pectoris. Am J Ther 1994, 1:93-101.
46. Stokes GS, Ryan M: Can extended-release isosorbide mononitrate be used as adjunctive therapy for systolic hypertension? An open study employing pulse-wave analysis to determine effects of antihypertensive therapy. Am J Geriatr Cardiol 1997, 6:11-19.